5e94: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Antibody-bound Glucagon-like Peptide-1 receptor extracellular domain== | ==Antibody-bound Glucagon-like Peptide-1 receptor extracellular domain== | ||
<StructureSection load='5e94' size='340' side='right' caption='[[5e94]], [[Resolution|resolution]] 2.00Å' scene=''> | <StructureSection load='5e94' size='340' side='right'caption='[[5e94]], [[Resolution|resolution]] 2.00Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5e94]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5E94 OCA]. For a <b>guided tour on the structure components</b> use [http:// | <table><tr><td colspan='2'>[[5e94]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5E94 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5E94 FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http:// | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5e94 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5e94 OCA], [http://pdbe.org/5e94 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5e94 RCSB], [http://www.ebi.ac.uk/pdbsum/5e94 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5e94 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
| Line 19: | Line 19: | ||
==See Also== | ==See Also== | ||
*[[3D structures | *[[Antibody 3D structures|Antibody 3D structures]] | ||
*[[Glucagon-like peptide 1 receptor|Glucagon-like peptide 1 receptor]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | |||
[[Category: Reedtz-Runge, S]] | [[Category: Reedtz-Runge, S]] | ||
[[Category: Schluckebier, G]] | [[Category: Schluckebier, G]] | ||
Revision as of 09:48, 22 April 2020
Antibody-bound Glucagon-like Peptide-1 receptor extracellular domainAntibody-bound Glucagon-like Peptide-1 receptor extracellular domain
Structural highlights
Function[GLP1R_HUMAN] This is a receptor for glucagon-like peptide 1. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Publication Abstract from PubMedThe Glucagon-like peptide-1 receptor (GLP-1R) is a member of the class B G protein-coupled receptor (GPCR) family and a well-established target for the treatment of type 2 diabetes. The N-terminal extracellular domain (ECD) of GLP-1R is important for GLP-1 binding and the crystal structure of the GLP-1/ECD complex was reported previously. The first structure of a class B GPCR transmembrane (TM) domain was solved recently, but the full length receptor structure is still not well understood. Here we describe the molecular details of antibody-mediated antagonism of the GLP-1R using both in vitro pharmacology and x-ray crystallography. We showed that the antibody Fab fragment (Fab 3F52) blocked the GLP-1 binding site of the ECD directly and thereby acts as a competitive antagonist of native GLP-1. Interestingly, Fab 3F52 also blocked a short peptide agonist believed to engage primarily the transmembrane and extracellular loop region of GLP-1R, whereas functionality of an allosteric small-molecule agonist was not inhibited. This study has implications for the structural understanding of the GLP-1R and related class B GPCRs, which is important for the development of new and improved therapeutics targeting these receptors. Structural insight into antibody-mediated antagonism of the Glucagon-like peptide-1 Receptor.,Hennen S, Kodra JT, Soroka V, Krogh BO, Wu X, Kaastrup P, Orskov C, Ronn SG, Schluckebier G, Barbateskovic S, Gandhi PS, Reedtz-Runge S Sci Rep. 2016 May 19;6:26236. doi: 10.1038/srep26236. PMID:27196125[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||